Thats where semaglutide helps bridge the gap
As observed in the STEP trials, treatment discontinuations due to AEs occurred in 2.4%7.0% of participants receiving semaglutide, compared with 1.0%4.6% of those receiving placebo [13, 38,39,40,41,42,43,44,45,46]
The Phase II Trial (NCT01349959) of azacitidine combined with entinostat in TNBC showed limited clinical efficacy, despite considering epigenetic changes (e.g., reduced methylation), indicating that better results could be achieved with higher dosages or combinatorial immunotherapy [241]
The disadvantage is precision at lower doses
Why Reconstitution Technique Actually Matters Tirzepatide ships freeze-dried for shelf stability, but the powder isn't usable until it's in solution at a known concentration